Old Web
English
Sign In
Acemap
>
authorDetail
>
Tanya Bogoslovsky
Tanya Bogoslovsky
Eisai
Disease
Medicine
open label
double blind
Placebo
3
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
BASELINE CHARACTERISTICS FOR CLARITY-AD: A PHASE 3 PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP, 18-MONTH STUDY EVALUATING BAN2401 IN EARLY ALZHEIMER’S DISEASE (3021)
2021
Neurology
Shau Yu Lynch
Michael C. Irizarry
Shobha Dhadda
Tanya Bogoslovsky
Larisa Reyderman
June Kaplow
Martin Rabe
Lynn D. Kramer
Harald Hampel
Chad J. Swanson
Show All
Source
Cite
Save
Citations (0)
BAN2401 In Early Alzheimer's Disease: A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With An Open-Label Extension Phase To Confirm Safety And Efficacy (1567)
2020
Neurology
Shau Yu Lynch
Michael C. Irizarry
Shobha Dhadda
Yong Zhang
Jinping Wang
Tanya Bogoslovsky
Larisa Reyderman
June Kaplow
Heather Bradley
Martin Rabe
Keiichiro Totsuka
Lynn D. Kramer
H Hampel
Chad J. Swanson
Show All
Source
Cite
Save
Citations (0)
A preliminary account of ARIA‐E in the ongoing open‐label extension phase of BAN2401‐G000‐201 in subjects with early Alzheimer’s disease: Human/Human trials: Anti‐amyloid
2020
Alzheimers & Dementia
Chad J. Swanson
Robert Lai
Tanya Bogoslovsky
Heather Bradley
Martin Rabe
Yong Zhang
Lynn D. Kramer
Show All
Source
Cite
Save
Citations (0)
1